- Home
- INCY
INCY
Incyte Corp.
as 02-05-2025 9:38am EST
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Upcoming Earnings Alert:
Get ready for potential market movements as Incyte Corp. INCY prepares to release earnings report on 10 Feb 2025.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 14.2B | IPO Year: | 1993 |
| Target Price: | $75.12 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -92.12 |
| 52 Week Low/High: | $50.35 - $83.95 | Next Earning Date: | 02-10-2025 |
| Revenue: | $4,075,860,000 | Revenue Growth: | 12.94% |
| Revenue Growth (this year): | 16% | Revenue Growth (next year): | 10.47% |
Stock Insider Trading Activity of Incyte Corp. (INCY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stein Steven H | INCY | EVP & Chief Medical Officer | Jan 17 '25 | Sell | $72.69 | 12,352 | $897,866.88 | 66,967 | |
| Tray Thomas | INCY | Principal Accounting Officer | Dec 13 '24 | Sell | $69.98 | 1,300 | $90,967.50 | 23,962 | |
| Iyengar Vijay K | INCY | EVP, GMAPPS | Nov 29 '24 | Sell | $75.49 | 6,043 | $455,543.71 | 36,341 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
Zacks
2 days ago
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Simply Wall St.
6 days ago
Exploring High Growth Tech Stocks In January 2025
MT Newswires
14 days ago
RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating
Business Wire
15 days ago
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
Zacks
16 days ago
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
MT Newswires
20 days ago
Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease
PR Newswire
21 days ago
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Compare INCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.